Chronic opioid therapy reduces nociceptive signaling through μ-opioid receptor–mediated inhibition of TRPV1 channels in primary afferent neurons.Opioid mortality HR 1.58-1.59Opioid OR 1.5 This silencing diminishes the low‑amplitude Ca²⁺ influx that normally activates CaMKK‑AMPK and SIRT3 pathways, a hormetic stimulus that promotes mitochondrial biogenesis, autophagy and NAD⁺‑dependent deacetylation.TRPV1 triggers CGRP via Ca2+-CaMK-CREBTRPV1 activation induces prolonged mitochondrial Ca2+ signaling Without this signal, mTORC1 remains preferentially active, driving anabolic growth and inflammaging.CGRP modulation linked to metabolism and longevity We hypothesize that the resulting shift in cellular energetics accelerates biological age, measurable by epigenetic clocks and the indole‑3‑propionic acid (IPA) metabolomic clock, and explains the excess mortality observed in long‑term opioid users.C5a-induced pain sensitization requires macrophages and TRPV1 Testable predictions: (1) Mice receiving chronic morphine will show decreased TRPV1‑dependent Ca²⁺ transients in dorsal root ganglia, reduced phospho‑AMPK and SIRT3 activity, increased phospho‑S6K (mTORC1 read‑out), and elevated epigenetic age relative to controls. (2) These mice will exhibit shortened lifespan and frailty indices. (3) Pharmacological rescue with low‑dose capsaicin (TRPV1 agonist) or AMPK activator (AICAR) will restore mitochondrial Ca²⁺ signaling, normalize AMPK/SIRT3 activity, dampen mTORC1, and extend lifespan despite continued opioid exposure. (4) In humans, individuals on chronic opioids will have lower plasma IPA levels and higher epigenetic age acceleration than matched non‑opioid controls, and supplementation with IPA will not fully mitigate the mortality risk if TRPV1 signaling remains suppressed. Falsifiability: If chronic opioid treatment does not alter TRPV1‑Ca²⁺ signaling, AMPK/SIRT3 activity, or epigenetic age, or if rescuing these pathways fails to improve survival, the hypothesis is refuted.